Ebola virus and severe acute respiratory syndrome coronavirus display late cell entry kinetics: Evidence that transport to NPC1+ endolysosomes is a rate-defining step

Journal of Virology

Volumn 89, Issue 5, 2015, Pages 2931-2943

  Mingo, Rebecca M ^a   Simmons, James A ^a   Shoemaker, Charles J ^a,b   Nelson, Elizabeth A ^a   Schornberg, Kathryn L ^a   D'Souza, Ryan S ^a   Casanova, James E ^a   White, Judith M ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN L; NIEMANN PICK C1; RECEPTOR PROTEIN; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN; CARRIER PROTEIN; MEMBRANE PROTEIN; NPC1 PROTEIN, HUMAN; VIROSOME;

ARTICLE; CONTROLLED STUDY; EBOLA VIRUS; ENDOLYSOSOME; ENDOSOME; ENZYME ACTIVITY; INTERNALIZATION; INTRACELLULAR TRANSPORT; LYSOSOME; NONHUMAN; PARTICLE SIZE; PINOCYTOSIS; PROTEIN LOCALIZATION; SARS CORONAVIRUS; VIRUS ENTRY; VIRUS LIKE AGENT; VIRUS MORPHOLOGY; CELL LINE; CHEMISTRY; EBOLAVIRUS; HUMAN; METABOLISM; PHYSIOLOGY; TIME; TRANSPORT AT THE CELLULAR LEVEL; VIROLOGY;

EBOLA VIRUS; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; SARS CORONAVIRUS;

BIOLOGICAL TRANSPORT; CARRIER PROTEINS; CELL LINE; EBOLAVIRUS; ENDOSOMES; HUMANS; LYSOSOMES; MEMBRANE GLYCOPROTEINS; SARS VIRUS; TIME FACTORS; VIROSOMES; VIRUS INTERNALIZATION;

EID: 84923050027     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.03398-14     Document Type: Article

References (59)

1. Feldmann H, Geisbert TW. 2011. Ebola haemorrhagic fever. Lancet 377:849-862. http://dx.doi.org/10.1016/S0140-6736(10)60667-8.
2. Hartman AL, Towner JS, Nichol ST. 2010. Ebola and Marburg hemorrhagic fever. Clin Lab Med 30:161-177. http://dx.doi.org/10.1016/j.cll.2009.12.001.
3. Gire SK, Goba A, Andersen KG, Sealfon RSG, Park DJ, Kanneh L, Jalloh S, Momoh M, Fullah M, Dudas G, Wohl S, Moses LM, Yozwiak NL, Winnicki S, Matranga CB, Malboeuf CM, Qu J, Gladden AD, Schaffner SF, Yang X, Jiang PP, Nekoui M, Colubri A, Coomber MR, Fonnie M, Moigboi A, Gbakie M, Kamara FK, Tucker V, Konuwa E, Saffa S, Sellu J, Jalloh AA, Kovoma A, Koninga J, Mustapha I, Kargbo K, Foday M, Yillah M, Kanneh F, Robert W, Massally JLB, Chapman SB, Bochicchio J, Murphy C, Nusbaum C, Young S, Birren BW, Grant DS, Scheiffelin JS, Lander ES, Happi C, Gevao SM, Gnirke A, Rambaut A, Garry RF, Khan SH, Sabeti PC. 2014. Genomic surveillance elucidates Ebola virus origin and transmission during the 2014 outbreak. Science 345:1369-1372. http://dx.doi.org/10.1126/science.1259657.
4. Chandran K. 2012. Filovirus entry into cells-new insights. Curr Opin Virol 2:206-214. http://dx.doi.org/10.1016/j.coviro.2012.02.015.
5. Hofmann-Winkler H, Kaup F, Pöhlmann S. 2012. Host cell factors in filovirus entry: novel players, new insights. Viruses 4:3336-3362. http://dx.doi.org/10.3390/v4123336.
6. Hunt CL, Lennemann NJ, Maury W. 2012. Filovirus entry: a novelty in the viral fusion world. Viruses 4:258-275. http://dx.doi.org/10.3390/v4020258.
7. White JM, Schornberg KL. 2012. A new player in the puzzle of filovirus entry. Nat Rev Microbiol 10:317-322. http://dx.doi.org/10.1038/nrmicro2764.
8. Côté M, Misasi J, Ren T, Bruchez A, Lee K, Filone CM, Hensley L, Li Q, Ory D, Chandran K, Cunningham J. 2011. Small molecule inhibitors reveal Niemann-Pick C1 is essential for Ebola virus infection. Nature 477: 344-348. http://dx.doi.org/10.1038/nature10380.
9. Carette JE, Raaben M, Wong AC, Herbert AS, Obernosterer G, Mulherkar N, Kuehne AI, Kranzusch PJ, Griffin AM, Ruthel G, Dal Cin P, Dye JM, Whelan SP, Chandran K, Brummelkamp TR. 2011. Ebola virus entry requires the cholesterol transporter Niemann-Pick C1. Nature 477: 340-343. http://dx.doi.org/10.1038/nature10348.
10. Miller EH, Obernosterer G, Raaben M, Herbert AS, Deffieu MS, Krishnan A, Ndungo E, Sandesara RG, Carette JE, Kuehne AI, Ruthel G, Pfeffer SR, Dye JM, Whelan SP, Brummelkamp TR, Chandran K. 2012. Ebola virus entry requires the host-programmed recognition of an intracellular receptor. EMBO J 31:1947-1960. http://dx.doi.org/10.1038/emboj.2012.53.
11. Ko DC, Gordon MD, Jin JY, Scott MP. 2001. Dynamic movements of organelles containing Niemann-Pick C1 protein: NPC1 involvement in late endocytic events. Mol Biol Cell 12:601-614. http://dx.doi.org/10.1091/mbc.12.3.601.
12. Cruz JC, Sugii S, Yu C, Chang T-Y. 2000. Role of Niemann-Pick type C1 protein in intracellular trafficking of low density lipoprotein-derived cholesterol. J Biol Chem 275:4013-4021. http://dx.doi.org/10.1074/jbc.275.6.4013.
13. Nunberg JH, York J. 2012. The curious case of arenavirus entry, and its inhibition. Viruses 4:83-101. http://dx.doi.org/10.3390/v4010083.
14. Lakadamyali M, Rust MJ, Babcock HP, Zhuang X. 2003. Visualizing infection of individual influenza viruses. Proc Natl Acad Sci USA 100: 9280-9285. http://dx.doi.org/10.1073/pnas.0832269100.
15. Lozach P-Y, Huotari J, Helenius A. 2011. Late-penetrating viruses. Curr Opin Virol 1:35-43. http://dx.doi.org/10.1016/j.coviro.2011.05.004.
16. Shoemaker CJ, Schornberg KL, Delos SE, Scully C, Pajouhesh H, Olinger GG, Johansen LM, White JM. 2013. Multiple cationic amphiphiles induce a Niemann-PickCphenotype and inhibit Ebola virus entry and infection. PLoS One 8:e56265. http://dx.doi.org/10.1371/journal.pone.0056265.
17. Delos SE, La B, Gilmartin A, White JM. 2010. Studies of the "chain reversal regions" of the avian sarcoma/leukosis virus (ASLV) and Ebolavirus fusion proteins: analogous residues are important, and a His residue unique to EnvA affects thepHdependence of ASLV entry. J Virol 84:5687-5694. http://dx.doi.org/10.1128/JVI.02583-09.
18. Spitzer M, Wildenhain J, Rappsilber J, Tyers M. 2014. BoxPlotR: a Web tool for generation of box plots. Nat Meth 11:121-122. http://dx.doi.org/10.1038/nmeth.2811.
19. Johannsdottir HK, Mancini R, Kartenbeck J, Amato L, Helenius A. 2009. Host cell factors and functions involved in vesicular stomatitis virus entry. J Virol 83:440-453. http://dx.doi.org/10.1128/JVI.01864-08.
20. Mire CE, White JM, Whitt MA. 2010. A spatio-temporal analysis of matrix protein and nucleocapsid trafficking during vesicular stomatitis virus uncoating. PLoS Pathog 6:e1000994. http://dx.doi.org/10.1371/journal.ppat.1000994.
21. Licata JM, Johnson RF, Han Z, Harty RN. 2004. Contribution of Ebola virus glycoprotein, nucleoprotein, and VP24 to budding of VP40 viruslike particles. J Virol 78:7344-7351. http://dx.doi.org/10.1128/JVI.78.14.7344-7351.2004.
22. Noda T, Sagara H, Suzuki E, Takada A, Kida H, Kawaoka Y. 2002. Ebola virus VP40 drives the formation of virus-like filamentous particles along with GP. J Virol 76:4855-4865. http://dx.doi.org/10.1128/JVI.76.10.4855-4865.2002.
23. Johansen LM, Brannan JM, Delos SE, Shoemaker CJ, Stossel A, Lear C, Hoffstrom BG, Dewald LE, Schornberg KL, Scully C, Lehár J, Hensley LE, White JM, Olinger GG. 2013. FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection. Sci Transl Med 5:190ra79. http://dx.doi.org/10.1126/scitranslmed.3005471.
24. Shoemaker CJ. 2012. Mechanisms of Ebolavirus entry. Ph.D. thesis. University of Virginia, Charlottesville, VA.
25. Iwasaki M, Ngo N, la Torre de JC. 2013. Sodium hydrogen exchangers contribute to arenavirus cell entry. J Virol 88:643-654. http://dx.doi.org/10.1128/JVI.02110-13.
26. Quirin K, Eschli B, Scheu I, Poort L, Kartenbeck J, Helenius A. 2008. Lymphocytic choriomeningitis virus uses a novel endocytic pathway for infectious entry via late endosomes. Virology 378:21-33. http://dx.doi.org/10.1016/j.virol.2008.04.046.
27. Lozach P-Y, Mancini R, Bitto D, Meier R, Oestereich L, Overby AK, Pettersson RF, Helenius A. 2010. Entry of bunyaviruses into mammalian cells. Cell Host Microbe 7:488-499. http://dx.doi.org/10.1016/j.chom.2010.05.007.
28. Saeed MF, Kolokoltsov AA, Freiberg AN, Holbrook MR, Davey RA. 2008. Phosphoinositide-3 kinase-Akt pathway controls cellular entry of Ebola virus. PLoS Pathog 4:e1000141. http://dx.doi.org/10.1371/journal.ppat.1000141.
29. Brecher M, Schornberg KL, Delos SE, Fusco ML, Saphire EO, White JM. 2012. Cathepsin cleavage potentiates the Ebola virus glycoprotein to undergo a subsequent fusion-relevant conformational change. J Virol 86: 364-372. http://dx.doi.org/10.1128/JVI.05708-11.
30. Schornberg K, Matsuyama S, Kabsch K, Delos S, Bouton A, White J. 2006. Role of endosomal cathepsins in entry mediated by the Ebola virus glycoprotein. J Virol 80:4147. http://dx.doi.org/10.1128/JVI.80.8.4147-4156.2006.
31. Wong AC, Sandesara RG, Mulherkar N, Whelan SP, Chandran K. 2010. A forward genetic strategy reveals destabilizing mutations in the Ebolavirus glycoprotein that alter its protease dependence during cell entry. J Virol 84:163-175. http://dx.doi.org/10.1128/JVI.01832-09.
32. Chandran K, Sullivan NJ, Felbor U, Whelan SP, Cunningham JM. 2005. Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection. Science 308:1643-1645. http://dx.doi.org/10.1126/science.1110656.
33. Belouzard S, Millet JK, Licitra BN, Whittaker GR. 2012. Mechanisms of coronavirus cell entry mediated by the viral spike protein. Viruses 4:1011-1033. http://dx.doi.org/10.3390/v4061011.
34. Heald-Sargent T, Gallagher T. 2012. Ready, set, fuse! The coronavirus spike protein and acquisition of fusion competence. Viruses 4:557-580. http://dx.doi.org/10.3390/v4040557.
35. Kawase M, Shirato K, van der Hoek L, Taguchi F, Matsuyama S. 2012. Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entry. J Virol 86:6537-6545. http://dx.doi.org/10.1128/JVI.00094-12.
36. Simmons G, Zmora P, Gierer S, Heurich A, Pöhlmann S. 2013. Proteolytic activation of the SARS-coronavirus spike protein: cutting enzymes at the cutting edge of antiviral research. Antiviral Res 100:605-614. http://dx.doi.org/10.1016/j.antiviral.2013.09.028.
37. Guha S, Padh H. 2008. Cathepsins: fundamental effectors of endolysosomal proteolysis. Indian J Biochem Biophys 45:75-90.
38. Rink J, Ghigo E, Kalaidzidis Y, Zerial M. 2005. Rab conversion as a mechanism of progression from early to late endosomes. Cell 122:735-749. http://dx.doi.org/10.1016/j.cell.2005.06.043.
39. Vonderheit A, Helenius A. 2005. Rab7 associates with early endosomes to mediate sorting and transport of Semliki forest virus to late endosomes. PLoS Biol 3:e233. http://dx.doi.org/10.1371/journal.pbio.0030233.
40. Lakadamyali M, Rust MJ, Zhuang X. 2006. Ligands for clathrin-mediated endocytosis are differentially sorted into distinct populations of early endosomes. Cell 124:997-1009. http://dx.doi.org/10.1016/j.cell.2005.12.038.
41. van Weering JRT, Verkade P, Cullen PJ. 2012. SNX-BAR-mediated endosome tubulation is co-ordinated with endosome maturation. Traffic 13:94-107. http://dx.doi.org/10.1111/j.1600-0854.2011.01297.x.
42. Blom TS. 2003. Defective endocytic trafficking of NPC1 and NPC2 underlying infantile Niemann-Pick type C disease. Hum Mol Genet 12:257-272. http://dx.doi.org/10.1093/hmg/ddg025.
43. Huang I-C, Bailey CC, Weyer JL, Radoshitzky SR, Becker MM, Chiang JJ, Brass AL, Ahmed AA, Chi X, Dong L, Longobardi LE, Boltz D, Kuhn JH, Elledge SJ, Bavari S, Denison MR, Choe H, Farzan M. 2011. Distinct patterns of IFITM-mediated restriction of filoviruses, SARS coronavirus, and influenza A virus. PLoS Pathog 7:e1001258. http://dx.doi.org/10.1371/journal.ppat.1001258.
44. Dyall J, Coleman CM, Hart BJ, Venkataraman T, Holbrook MR, Kindrachuk J, Johnson RF, Olinger GG, Jahrling PB, Laidlaw M, Johansen LM, Lear-Rooney CM, Glass PJ, Hensley LE, Frieman MB. 2014. Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrob Agents Chemother 58:4885-4893. http://dx.doi.org/10.1128/AAC.03036-14.
45. Burkard C, Verheije MH, Wicht O, van Kasteren SI, van Kuppeveld FJ, Haagmans BL, Pelkmans L, Rottier PJM, Bosch BJ, de Haan CAM. 2014. Coronavirus cell entry occurs through the endo-/lysosomal pathway in a proteolysis-dependent manner. PLoS Pathog 10:e1004502. http://dx.doi.org/10.1371/journal.ppat.1004502.
46. Bertram S, Glowacka I, Müller MA, Lavender H, Gnirss K, Nehlmeier I, Niemeyer D, He Y, Simmons G, Drosten C, Soilleux EJ, Jahn O, Steffen I, Pöhlmann S. 2011. Cleavage and activation of the severe acute respiratory syndrome coronavirus spike protein by human airway trypsin-like protease. J Virol 85:13363-13372. http://dx.doi.org/10.1128/JVI.05300-11.
47. Simmons G. 2005. Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry. Proc Natl Acad Sci USA 102:11876-11881. http://dx.doi.org/10.1073/pnas.0505577102.
48. Matsuyama S, Ujike M, Morikawa S, Tashiro M, Taguchi F. 2005. Protease-mediated enhancement of severe acute respiratory syndrome coronavirus infection. Proc Natl Acad Sci USA 102:12543-12547. http://dx.doi.org/10.1073/pnas.0503203102.
49. Haines KM, Vande Burgt NH, Francica JR, Kaletsky RL, Bates P. 2012. Chinese hamster ovary cell lines selected for resistance to Ebolavirus glycoprotein mediated infection are defective for NPC1 expression. Virology 432:20-28. http://dx.doi.org/10.1016/j.virol.2012.05.018.
50. Hood CL, Abraham J, Boyington JC, Leung K, Kwong PD, Nabel GJ. 2010. Biochemical and structural characterization of cathepsin L-processed Ebola virus glycoprotein: implications for viral entry and immunogenicity. J Virol 84:2972-2982. http://dx.doi.org/10.1128/JVI.02151-09.
51. Misasi J, Chandran K, Yang JY, Considine B, Filone CM, Cote M, Sullivan N, Fabozzi G, Hensley L, Cunningham J. 2012. Filoviruses require endosomal cysteine proteases for entry but exhibit distinct protease preferences. J Virol 86:3284-3292. http://dx.doi.org/10.1128/JVI.06346-11.
52. Marzi A, Reinheckel T, Feldmann H. 2012. Cathepsin B & L are not required for Ebola virus replication. PLoS Negl Trop Dis 6:e1923. http://dx.doi.org/10.1371/journal.pntd.0001923.
53. Gregory SM, Harada E, Liang B, Delos SE, White JM, Tamm LK. 2011. Structure and function of the complete internal fusion loop from Ebolavirus glycoprotein 2. Proc Natl Acad SciUSA108:11211-11216. http://dx.doi.org/10.1073/pnas.1104760108.
54. Harrison JS, Koellhoffer JF, Chandran K, Lai JR. 2012. Marburg virus glycoprotein GP2: pH-dependent stability of the ectodomain α-helical bundle. Biochemistry 51:2515-2525. http://dx.doi.org/10.1021/bi3000353.
55. Shah PP, Wang T, Kaletsky RL, Myers MC, Purvis JE, Jing H, Huryn DM, Greenbaum DC, Smith AB, Bates P, Diamond SL. 2010. A smallmolecule oxocarbazate inhibitor of human cathepsin L blocks severe acute respiratory syndrome and Ebola pseudotype virus infection into human embryonic kidney 293T cells. Mol Pharmacol 78:319-324. http://dx.doi.org/10.1124/mol.110.064261.
56. Adedeji AO, Severson W, Jonsson C, Singh K, Weiss SR, Sarafianos SG. 2013. Novel inhibitors of severe acute respiratorysyndromecoronavirus entry that act by three distinct mechanisms. J Virol 87:8017-8028. http://dx.doi.org/10.1128/JVI.00998-13.
57. Elshabrawy HA, Fan J, Haddad CS, Ratia K, Broder CC, Caffrey M, Prabhakar BS. 2014. Identification of a broad-spectrum antiviral small molecule against SARS-CoV, Ebola, Hendra, and Nipah viruses using a novel high throughput screening assay. J Virol 88:4353-4365. http://dx.doi.org/10.1128/JVI.03050-13.
58. Mainou BA, Dermody TS. 2012. Transport to late endosomes is required for efficient reovirus infection. J Virol 86:8346-8358. http://dx.doi.org/10.1128/JVI.00100-12.
59. Díaz-Salinas MA, Silva-Ayala D, López S, Arias CF. 2014. Rotaviruses reach late endosomes and require the cation-dependent mannose-6-phosphate receptor and the activity of cathepsin proteases to enter the cell. J Virol 88:4389-4402. http://dx.doi.org/10.1128/JVI.03457-13.